This inventor holds 3 USPTO granted patents and 7 published patent applications and 3 EPO patents. Top assignee: Biocompatibles UK Limited. Active years: 2013-2014.
Company Filing History:
Years Active: 2013-2014
Title: Christine Wallrapp: Innovator in GLP-1 Peptide Technologies
Introduction
Christine Wallrapp is a notable inventor based in Grossostheim, Germany. She has made significant contributions to the field of peptide technology, particularly in the development of GLP-1 fusion peptides. With a total of 3 patents, her work focuses on innovative solutions for treating various diseases.
Latest Patents
One of her latest patents involves GLP-1 fusion peptides that exhibit enhanced stability in vivo. This invention provides fusion peptides that resist degradation by dipeptidyl peptidase IV, which is crucial for maintaining their therapeutic efficacy. The fusion peptide comprises a GLP-1 sequence and a peptide sequence of at least nine amino acids, which can be used in the treatment of diabetes and neurodegenerative disorders. Another significant patent is for spherical microcapsules that contain GLP-1 peptides. These microcapsules are designed with cross-linked polymers and are capable of expressing and secreting GLP-1 peptides, making them useful for treating type 2 diabetes and related conditions.
Career Highlights
Christine Wallrapp is currently associated with Biocompatibles UK Limited, where she continues to advance her research in peptide technologies. Her innovative work has positioned her as a key figure in the development of new therapeutic approaches.
Collaborations
Christine has collaborated with notable colleagues such as Eric Thoenes and Peter Geigle, contributing to the advancement of her research and the successful development of her patents.
Conclusion
Christine Wallrapp's contributions to GLP-1 peptide technologies highlight her role as an influential inventor in the field. Her innovative patents and ongoing research continue to pave the way for new treatments for various diseases.